Evidence map›Paper›PMID 36851112›Full record

ArticleVaccines2023

The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as a Case Study.

Manuela Di Fusco, Diana Mendes, Lotte Steuten, David E Bloom, Michael Drummond, Katharina Hauck, Jonathan Pearson-Stuttard, Rachel Power, David Salisbury, Adrian Towse and 4 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. What is new in the early health technology assessment's new definition?International journal of technology assessment in health care · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Manuela Di FuscoHealth Economics and Outcomes Research, Pfizer Inc., New York, NY 10017, USA.
Diana MendesHealth & Value, Pfizer Co., Ltd., Tadworth KT20 7NS, UK.
Lotte SteutenOffice of Health Economics, London SW1E 6QT, UK.
David E BloomDepartment of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
Michael DrummondCentre for Health Economics, Alcuin A Block, University of York, Heslington, York YO10 5DD, UK.
Katharina HauckDepartment of Infectious Disease Epidemiology, Faculty of Medicine, School of Public Health, Imperial College London, London W2 1PG, UK.
Jonathan Pearson-StuttardDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, UK.
Rachel PowerThe Patients Association, PO Box 935, Harrow HA1 3YJ, UK.
David SalisburyProgramme for Global Health, Royal Institute of International Affairs, Chatham House, London SW1Y 4LE, UK.
Adrian TowseOffice of Health Economics, London SW1E 6QT, UK.
Julie RoizEvidence, Value and Access by PPD, Evidera, London W6 8BJ, UK.
Gabor SzaboEvidence, Value and Access by PPD, Evidera, H-1113 Budapest, Hungary.
Jingyan YangHealth Economics and Outcomes Research, Pfizer Inc., New York, NY 10017, USA.ORCID 0000-0001-5523-649X
Kinga MarczellEvidence, Value and Access by PPD, Evidera, H-1113 Budapest, Hungary.
Imperial College London · GBOffice Of Health Economics · GBPfizer (United States) · USChatham House · GBHarvard Global Health Institute · USPfizer (United Kingdom) · GBThe Patients Association · GBUniversity of York · GB

Funding

Medical Research Council MR/R015600/1
6 · The paper itself

Abstract

Health technology assessments (HTAs) of vaccines typically focus on the direct health benefits to individuals and healthcare systems. COVID-19 highlighted the widespread societal impact of infectious diseases and the value of vaccines in averting adverse clinical consequences and in maintaining or resuming social and economic activities. Using COVID-19 as a case study, this research work aimed to set forth a conceptual framework capturing the broader value elements of vaccines and to identify appropriate methods to quantify value elements not routinely considered in HTAs. A two-step approach was adopted, combining a targeted literature review and three rounds of expert elicitation based on a modified Delphi method, leading to a conceptual framework of 30 value elements related to broader health effects, societal and economic impact, public finances, and uncertainty value. When applying the framework to COVID-19 vaccines in post-pandemic settings, 13 value elements were consensually rated highly important by the experts for consideration in HTAs. The experts reviewed over 10 methods that could be leveraged to quantify broader value elements and provided technical forward-looking recommendations. Limitations of the framework and the identified methods were discussed. This study supplements ongoing efforts aimed towards a broader recognition of the full societal value of vaccines.

Indexed as

COVID-19COVID-19 vaccinationDelphiexpert consensushealth technology assessmentsocietal impactvaccinesvaccine value

Identifiers

PMID36851112
PMCPMC9961127
OpenAlexW4317621284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.